Charles Richter King
Plus aucun poste en cours
Profil
Charles Richter King was Senior Vice President of Research for GenVec, Inc. until April 15, 2009.
He joined GenVec in 1998.
Previously, he was Vice President of New Product Research for GenVec and Director of Drug Discovery for Oncologix.
Dr. King directed an experienced research group at the Georgetown University Medical School's Lombardi Cancer Research Center in Washington, DC, where he served as Associate Professor with the University's Department of Biochemistry.
He received a PhD in Biochemistry from Johns Hopkins University.
Anciens postes connus de Charles Richter King
| Sociétés | Poste | Fin |
|---|---|---|
| GENVEC INC | Directeur Technique/Scientifique/R&D | 15/04/2009 |
| AGENUS INC. | Directeur/Membre du Conseil | - |
Formation de Charles Richter King
| The Johns Hopkins University | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| AGENUS INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
GenVec, Inc.
 GenVec, Inc. Pharmaceuticals: MajorHealth Technology GenVec, Inc. operated as a clinical-stage gene delivery company, which engaged in the development of therapeutics and vaccines. The firm designs, tests, and manufactured adenoviral-based product candidates using its proprietary AdenoVerse platform. Its products included CGF166-Hearing Loss; GV2311-RSV Vaccine; and GV2207-HSV-2 Immunotherapeutic. The company was founded in December 1992 and was headquartered in Rockville, MD. | Health Technology |
